ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1398	National Cancer Institute	Html	en	Skin Cancer Prevention (PDQ®)–Patient Version	Expert-reviewed information summary about factors that may influence the risk of developing skin cancer and about research aimed at the prevention of this disease.	skin cancer risk 0.467928 skin cancer 0.941497 cancer treatment 0.38312 cancer prevention trials 0.475588 skin cancer prevention 0.535336 prevention clinical trials 0.429013 protective factors 0.444137 following PDQ summaries 0.42969 PDQ cancer information 0.571591 recurrent nonmelanoma skin 0.412014 squamous cells 0.377891 Clinical Trials section 0.386332 clinical trials 0.585589 cancer information summary 0.499343 melanoma skin cancer 0.517983 breast cancer prevention 0.410906 cancer patients 0.382129 latest published information 0.38194 cancer risk factor 0.448186 NCI’s PDQ 0.391159 UV radiation 0.512203 NCI PDQ cancer 0.462016 basal cell carcinoma 0.591274 new cases 0.414085	PDQ Screening 0.380155 cancer risk factors 0.449906 Cancer prevention 0.618596 cancer protective factor 0.429755 new skin cancers 0.427053 new actinic keratoses 0.38071 Cancer Information Service 0.419558 slightly lower rates 0.381858 nonmelanoma skin cancers 0.666071 Prevention Editorial Board 0.428923 treatment clinical trials 0.387193 National Cancer Institute 0.507676 PDQ documents 0.381747 D. The skin 0.379577 new treatment 0.382048 Cancer Care page 0.40764 PDQ database 0.385226 PDQ summary 0.416284 melanoma prevention trials 0.402284 cancer clinical trials 0.430331 risk factors 0.646155 cancer information summaries 0.426847 nonmelanoma skin cancer 0.802884 comprehensive cancer information 0.42608	CLICK HERE
1482	National Cancer Institute	Html	en	Thyroid Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of thyroid cancer.	NX Regional lymph 0.514232 differentiated thyroid carcinoma 0.483242 thyroid capsule 0.458348 lymph node recurrence 0.424478 lymph node involvement. 0.433258 thyroid carcinoma 0.494127 follicular thyroid carcinoma 0.43746 minimal extrathyroid extension 0.497486 papillary thyroid cancer 0.500545 recurrent differentiated thyroid 0.423584 perithyroid soft tissues 0.49864 M0 T2 Tumor 0.418332 N1a Metastases 0.452974 patients 0.4225 lymph node biopsy 0.465877 sentinel lymph node 0.465511 thyroid cancer. 0.408942 encases carotid artery 0.459248 lymph nodes 0.70121 papillary thyroid microcarcinomas 0.421769 papillary thyroid carcinoma 0.467474 prelaryngeal/Delphian lymph nodes 0.599278 T1b Tumor 0.476542 thyroid diseases 0.408003	T1a Tumor 0.476741 thyroid gland 0.406975 thyroid cancer 0.570421 mediastinal lymph nodes 0.577558 thyroid autoantibodies 0.408316 greatest dimension 0.710356 follicular thyroid cancer 0.472046 subcutaneous soft tissues 0.453725 soft tissues 0.502801 recurrent laryngeal nerve 0.458581 superior mediastinal lymph 0.567495 tumor suppressor gene 0.41425 regional lymph node 0.969698 distant metastasis 0.429776 TX Primary tumor 0.476275 cm 0.593737 primary tumor 0.496822 lymph node status 0.43297 differentiated thyroid cancer 0.496492 lymph node involvement 0.43209 M0 T1 Tumor 0.448756 tumor 0.667722 regional lymph nodes 0.569893 lymph node metastases 0.446319	CLICK HERE
1496	National Cancer Institute	Html	en	Chronic Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of chronic myeloproliferative neoplasms.	chronic idiopathic myelofibrosis 0.460932 -associated myelofibrosis 0.377277 primary myelofibrosis 0.76249 agnogenic myeloid metaplasia 0.307689 prognostic factors 0.222887 peripheral blood 0.22296 Mayo Clin Proc 0.241864 Lasho TL 0.217158 Br J Haematol 0.259671 blood cell transfusions 0.218297 Engl J Med 0.445409 red blood cell 0.333388 aforementioned prognostic systems 0.209417 JAK2-negative primary myelofibrosis 0.455533 Myelofibrosis Research 0.385033 peripheral blood myelophthisis 0.21294 Mesa RA 0.470382 myeloid metaplasia 0.871911 myeloproliferative neoplasms 0.310964 teardrop-shaped red blood 0.217055 myelofibrosis 0.915542 retrospective review 0.217962 Vera Study Group 0.206315 Abstract 0.596486	therapy 0.209486 patients 0.479624 Clin Oncol 0.364567 postoperative subcutaneous heparin 0.256357 Bone Marrow Transplant 0.217694 blood 0.376461 bone marrow 0.283097 thrombocythemia myelofibrosis 0.453249 blood cell survival 0.22308 peripheral blood granulocytes 0.213686 idiopathic myelofibrosis 0.478488 Asymptomatic low-risk patients 0.236666 Leuk Lymphoma 0.295111 International Prognostic Scoring 0.257794 clinical prognostic parameters 0.20507 high phlebotomy requirement 0.203305 post–essential thrombocythemia myelofibrosis 0.447393 allogeneic stem cell 0.353702 low-risk patients 0.238481 acute myelofibrosis 0.423026 blood cell transfusion 0.227086 et al. 0.52463 JAK inhibitors 0.215327	CLICK HERE
1582	National Cancer Institute	Html	en	Adult Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version	Soft tissue sarcomas can form almost anywhere in the body, but are most common in the head, neck, arms, legs, truck, and abdomen. Find out about risk and genetic factors, symptoms, tests to diagnose, prognosis, staging, and treatment for soft tissue sarcoma.	cancer treatment 0.262443 malignant tumor cells 0.254786 cancer spreads 0.245112 body 0.294182 type 0.25634 PDQ cancer information 0.274383 clinical trial search 0.274958 clinical trials 0.461076 nearby lymph nodes 0.239706 cancer information summary 0.260539 clinical trial 0.328582 patients 0.25186 blood vessels 0.240907 treatment clinical trial 0.238552 subcutaneous tissue 0.292398 NCI PDQ cancer 0.240642 Treatment Option Overview 0.242732 lymph nodes 0.261315 radiation therapy 0.391981 little normal tissue 0.262689 soft tissue sarcoma 0.92025 General information 0.241563 treatment 0.357792 wide local excision 0.284219 nearby healthy tissue 0.249677	NCI-supported cancer 0.247977 cancer cells 0.331726 laboratory test 0.23958 soft tissues 0.24063 connective tissue 0.264853 treatment clinical trials 0.254055 National Cancer Institute 0.283258 soft tissue sarcomas 0.301359 new treatment 0.260355 adult soft tissue 0.678017 tissue sarcoma cells 0.278793 external radiation therapy 0.248848 primary tumor 0.244329 metastatic tumor 0.239026 tissue samples 0.246374 Regional hyperthermia therapy 0.239395 cancer clinical trials 0.280749 stage 0.259627 tumor 0.3265 Tissue Sarcoma Treatment 0.274121 treatment options 0.240625 internal radiation therapy 0.238752 cancer 0.489567 information 0.283228	CLICK HERE
1695	National Cancer Institute	Html	en	High-Dose Vitamin C (PDQ®)–Health Professional Version	Expert-reviewed information summary about the use of high-dose vitamin C as a treatment for people with cancer.	ascorbic acid cause 0.642882 prostate cancer cell 0.630423 /IV ovarian cancer 0.57305 oral ascorbic acid 0.649173 vitamin C therapy 0.612109 vitamin C. 0.610223 cancer information summary 0.591614 weekly ascorbate infusions 0.607343 multiple myeloma patients 0.578578 ovarian cancer 0.574477 cancer patients 0.68661 vitamin 0.72459 high-dose vitamin 0.665873 oral vitamin 0.706163 significant adverse events 0.605455 high-dose IV ascorbate 0.593412 colon cancer cells 0.587994 ascorbic acid treatment 0.848969 metastatic colorectal cancer 0.572155 vitamin C supplements 0.616683 ascorbic acid 0.99701 study 0.585466 current clinical trials 0.571291 case series 0.594589 tumor volume 0.583085	pancreatic cancer patients 0.683645 dehydroascorbic acid 0.640204 terminal cancer patients 0.626123 cancer cells 0.588032 bortezomib growth inhibition 0.576885 high-dose ascorbic acid 0.717915 studies 0.596394 pharmacological ascorbate 0.581055 breast cancer cells. 0.579255 decrease cell proliferation 0.57116 ascorbic acid synthesis 0.660705 cancer cell lines. 0.642672 L-ascorbic acid 0.574809 intracellular ascorbic acid 0.648545 high-dose IV vitamin 0.658734 healthy volunteers 0.583492 inhibitory effect 0.590166 cancer cell death 0.591483 oxidized form 0.602818 cancer cell xenografts 0.58194 ascorbic acid. 0.583971 ascorbate 0.663468 tumor inhibitory effect 0.580256 cancer 0.692622	CLICK HERE
1775	National Cancer Institute	Html	es	Náuseas y vómitos relacionados con el tratamiento (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de las náuseas y los vómitos como complicaciones a causa del cáncer o su tratamiento. Se describen abordajes de tratamiento de las náuseas y los vómitos.	chemotherapy induced nausea 0.342573 conditioned nausea 0.336948 Bouganim N 0.33134 delayed chemotherapy-induced nausea 0.334556 anticipatory nausea 0.772561 schwartzberg ls 0.356266 horas vo 0.591535 Krozely MG 0.34156 Hesketh PJ 0.353455 colorectal cancer 0.336446 chemotherapy-induced nausea 0.951327 dosis vo 0.347133 continuación presente nva 0.332752 mg vr 0.340801 community clinical practices 0.338332 anticipatory emesis 0.337674 cancer chemotherapy 0.773091 Pain Symptom Manage 0.361458 Support Oncol 0.346357 quimioterapia categoría 0.357422 Roscoe JA 0.415752 NyV agudos 0.347107 mg im 0.432997 NVIQ agudos 0.337444 controlling chemotherapy-induced nausea 0.364663	delayed nausea 0.337245 Care Cancer 0.464148 Bovbjerg DH 0.349781 VO Inhibidor 0.357448 mg vo 0.767769 quimioterapia vo 0.485969 Kris MG 0.406292 quimioterapia vo la 0.389831 significant clinical problem 0.339573 Prospective validation 0.334589 Consult Clin Psychol 0.417355 clinical oncology 0.347599 quimioterapia iv 0.373245 Hickok JT 0.353347 días vo inhibidor 0.344362 chemotherapy patients 0.331687 Clin Oncol 0.384683 sistema nervioso central 0.357893 patients treated 0.340656 días vo 0.360421 Morrow GR 0.513036 potencial emetógeno 0.502334 Clinical roundtable monograph 0.340704 Adv Hematol Oncol 0.339165	CLICK HERE
1944	National Cancer Institute	Html	es	Síndromes cardiopulmonares (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca de las afecciones comunes que producen síntomas en el pecho. Los síndromes cardiopulmonares que se exponen en este sumario son la disnea relacionada con el cáncer, la efusión pleural maligna, la efusión pericárdica y el síndrome de la vena cava superior.	neoplásico pericárdico 0.570337 aurículas derecha 0.413336 siguientes procedimientos 0.476145 suficiente sangre 0.429294 disnea ayuda 0.428346 siguientes elementos 0.427349 PDQ Síndromes cardiopulmonares 0.420075 aurícula derecha 0.413308 pequeña cantidad 0.419135 líquido allí 0.447596 cuerpo.ampliar radiografía 0.576347 siguientes tipos 0.416182 síndromes cardiopulmonares 0.693009 rayos x 0.496155 suficiente oxígeno 0.422453 largo plazo 0.415907 menudo causa infecciones 0.442964 esclerosis pericárdica procedimiento 0.439765 obstructiva crónica 0.420705 pleural extracción 0.480399 vías respiratorias 0.858731	máxima presión 0.42053 National Cancer Institute 0.411568 pleural maligno 0.991379 vía respiratoria 0.496611 suficiente aire 0.455692 Ascitis Extracción 0.422054 siguientes tratamientos 0.411554 pequeñas vías respiratorias 0.434391 Pericardiotomía Procedimiento 0.427972 Instituto Nacional 0.420501 pericárdico extracción 0.450036 siguientes problemas 0.422606 siguientes factores 0.415522 Physician Data Query 0.44175 haz angosto 0.421283 linfangitis carcinomatosa terapia 0.435827 Pericardiectomía Cirugía 0.416216 mala nutrición 0.417318 insuficiencia cardíaca 0.522457 superior quimioterapia 0.453603 procedimiento ayuda 0.419009	CLICK HERE
2057	National Cancer Institute	Html	es	Cáncer de hueso	Hoja informativa acerca del diagnóstico y tratamiento de los cánceres que se presentan en los huesos.	Lippincott Williams 0.528921 Pediatric Oncology 0.425852 DeVita VT 0.423199 Grandes avances 0.423263 Fischbach FT 0.422317 tejido óseo 0.925192 rayos x 0.477476 American Cancer Society 0.521554 página web guía 0.432205 7th ed 0.466045 altas dosis 0.425962 enfermedades infantiles congénitas 0.446544 Diagnostic Tests 0.424605 fosfatasa alcalina 0.483649 distintos tipos 0.471502 médico pregunta 0.42954 Pizzo P 0.423691 Estados Unidos 0.422015 survival among children 0.439442 Boice JD 0.42308 Rosenberg SA 0.420738 Fraumeni JF 0.42331 tumor óseo 0.736727 Schottenfeld D 0.42165	States SEER Program 0.439663 importante opción 0.422974 mejores formas 0.420225 pequeña cantidad 0.471903 editors.  cancer 0.434055 gammagrafía ósea 0.428461 O'Sullivan B 0.421908 Malawer MM 0.422909 Curtis RE 0.421362 probables beneficios 0.422945 National Cancer Institute 0.447941 4th ed 0.425929 Ries LAG 0.424185 Ewing Sarcoma Family 0.452617 Hellman S 0.421499 Dunning MB 0.422439 Retrieved March 0.423884 emission tomography 0.426368 enzima llamada 0.426279 cabo estudios 0.429851 Helman LJ 0.424392 Gurney JG 0.42319 Poplack DG 0.422887 Miller RW 0.421236	CLICK HERE
15484	National Cancer Institute	Html	null	Cancer Moonshot Milestones	A collection of links to press releases, fact sheets, blog posts, and other materials documenting the latest Moonshot Initiative activities and milestones.			CLICK HERE
15648	National Cancer Institute	Html	en	NCI Grant Policies	Research grants are subject to a variety of policy requirements. Find highlights of policy announcements or changes specific to NCI.	Large R01s 0.450134 intramural investigators 0.495879 P01 renewal applications 0.616984 comprehensive access 0.459855 research grants 0.682427 specific policy 0.488359 evidence-based approaches 0.457301 human health 0.466536 Access Policy 0.490853 cancer therapy 0.46631 budget request 0.487575 prior approval 0.46826 clinical trials 0.978226 alternative calculation 0.447591 NIH Grants Policy 0.785706 additional information 0.464918 unsolicited R01 applications 0.694664 exceptions 0.333503 NIH GDS policy 0.707591 cooperative agreements 0.455552 research results 0.500906 direct cost requests 0.569063 PARs 0.332254 grants administration policies 0.684335 cancer research continuum 0.601742	NCI-Supported Interventional Clinical 0.650424 non-NIH funded investigators 0.630213 NIH research 0.564712 contracts 0.352239 large R01 payline 0.833282 NCI Clinical Trials 0.784254 genomic research data 0.651702 final results 0.607682 general R01 payline 0.832292 NCI Program Director 0.732659 Scientific Review 0.449688 budget format 0.487382 grantees 0.329888 NIH Guide 0.534988 interventional clinical trials 0.88994 deviation 0.332851 directly impact patient 0.587395 policy announcements 0.520246 Type 0.343808 policy requirements 0.522004 separate NCI payline 0.844339 interventional cancer research 0.663219 prior project period 0.601145 direct cost budget 0.622892	CLICK HERE